MicroTransponder Welcomes Dana G. Mead, Jr. as New Chair and Adds Cynthia Lucchese as Independent Director

MicroTransponder Strengthens Leadership Team

In a significant move for its strategic governance, MicroTransponder®, Inc., a leading medical technology company, has appointed Dana G. Mead, Jr. as the new Chair of its Board of Directors. Alongside him, Cynthia Lucchese has joined the Board as an independent director. This announcement comes as MicroTransponder continues to enhance its operations surrounding the Vivistim® Paired VNS™ System, a groundbreaking therapy aimed at aiding recovery for individuals affected by chronic strokes.

Richard Foust, the CEO of MicroTransponder, expressed his enthusiasm regarding these appointments, emphasizing the substantial experience both Mead and Lucchese bring to the table. "It is a privilege to have Dana and Cindy on our Board. Their deep industry and governance experience will be invaluable as we scale U.S. commercialization and work to establish Vivistim Paired VNS as the new standard of care in stroke recovery," Foust stated.

Profiles of the New Board Members

Dana G. Mead, Jr. is no stranger to the medical technology sector, boasting a wealth of experience in guiding commercial-stage companies through pivotal growth phases. His notable portfolio includes positions on the boards of a plethora of medical companies such as Inspire Medical Systems and BVI Medical, among others. Previously, he served as President and CEO of HeartFlow and BVI Medical. Mead's vision aligns with MicroTransponder's mission of improving the lives of stroke survivors.

"MicroTransponder's mission to restore movement and independence for stroke survivors is deeply compelling," Mead noted. He pointed out the strong engagement from healthcare professionals and positive patient outcomes, reinforcing his eagerness to guide the company’s growth journey.

On the other hand, Cynthia Lucchese adds over three decades of financial and operational expertise in healthcare to the Board. Currently, she serves on the boards of CooperCompanies and BVI Medical, having previously held senior roles in various medical firms, including Penske Entertainment and Hillenbrand. Her in-depth understanding of the medical device landscape will play a crucial role in MicroTransponder's future.

Lucchese expressed her motivations clearly: "MicroTransponder has an exceptional team and a profoundly meaningful mission. I look forward to contributing to its exciting impact and future."

The introduction of Mead and Lucchese is a strategic decision aimed at accelerating the adoption of the Vivistim Paired VNS Therapy across premier stroke centers nationwide. This therapy has become a beacon of hope for stroke victims, generating 2-3 times more improvements in upper limb functionality compared to traditional therapies.

MicroTransponder is dedicated to transforming stroke care through innovative solutions, and the addition of these prominent figures to its leadership team signifies a committed step toward its goal of establishing Vivistim as the gold standard in stroke recovery.

As the company gears up for significant growth and more widespread adoption of their therapy, the upcoming initiatives under the guidance of Mead and Lucchese are anticipated to lead to substantial advancements in neurologic care. For more insights into the company and its mission, you can visit MicroTransponder or learn more about the Vivistim® Paired VNS™ System at Vivistim Health Pros.